Skip to main content

Colleen Hadigan, MD, MPH

chadigan.jpg

Colleen Hadigan, MD, MPH

Chief Medical Officer & Clinical Director

Chief Medical Officer & Clinical Director, NIH Clinical Center
hadiganc@nih.gov
301-496-3516

Dr. Colleen Hadigan is the Chief Medical Officer and Clinical Director of the NIH Clinical Center.

BA, Barnard College
MD, Johns Hopkins School of Medicine
MPH, Harvard School of Public Health

Dr. Hadigan received her medical degree from the Johns Hopkins School of Medicine and subsequently completed her residency in Pediatrics at Boston Children’s Hospital followed by a fellowship in Pediatric Gastroenterology and Hepatology in the Harvard Combined Program for Pediatric Gastroenterology, Hepatology and Nutrition at Boston Children’s Hospital and Massachusetts General Hospital. She also received her MPH at the Harvard School of Public Health.

Dr. Hadigan’s academic medical career has been primarily centered in clinical research with much of the focus on the long-term and metabolic complications of HIV and its therapies in both children and adults. In 2006, she came to the National Institutes of Health as a member of the Laboratory of Immunoregulation of the National Institute of Allergy and Infectious Disease (NIAID). In addition to her active research and mentoring, Dr. Hadigan served as the Deputy Manager of the NIAID Outpatient HIV and Infectious Diseases Research Clinic for over 10 years. In October of 2021 she became the Chief Medical Officer and Clinical Director for the NIH Clinical Center. She is board certified in Pediatrics and Pediatric GI and Hepatology and remains clinically active as the Pediatric GI and Hepatology consultant for the NIH Clinical Center.

  • NIH Clinical Center, Staff Clinician of the Year, NIH, 2018
  • Kirk Miller Award for Excellence in HIV Clinical Care, NIH, 2010
  • Attending of the Year, Harvard Combined Program in Pediatric GI and Nutrition, 2005
  • Alpha Omega Alpha, Johns Hopkins School of Medicine, 1995

Fourman LT, Billingsley JM, Agyapong G, Ho Sui SJ, Feldpausch MN, Purdy J, Zheng I, Pan CS, Corey KE, Torriani M, Kleiner DE, Hadigan CM, Stanley TL, Chung RT, Grinspoon SK. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight. 2020 Aug 20;5(16):e140134.

Balmaceda JB, Aepfelbacher J, Belliveau O, Chaudhury CS, Chairez C, McLaughlin M, Silk R, Gross C, Kattakuzhy S, Rosenthal E, Kottilil S, Kleiner DE, Hadigan C. Long-term changes in hepatic fibrosis following hepatitis C viral clearance in patients with and without HIV. Antivir Ther. 2019 Jul 30.

Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, Aepfelbacher J, Buckless C, Tsao A, Kellogg A, Branch K, Lee H, Liu CY, Corey KE, Chung RT, Torriani M, Kleiner DE, Hadigan CM, Grinspoon SK. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019 Dec;6(12):e821-e830.

Unsal AB, Mattingly AS, Jones SE, Purdy JB, Reynolds JC, Kopp JB, Hazra R, Hadigan CM. Effect of Antiretroviral Therapy on Bone and Renal Health in Young Adults Infected with HIV in Early Life. J Clin Endocrinol Metab. 2017 Aug 1;102(8):2896-2904.

Gordon LA, Kumar P, Brooks KM, Kellogg A, McManus M, Alfaro RM, Nghiem K, George JM, Lozier J, Penzak SR, Hadigan C. Antiretroviral Boosting Agent Cobicistat Increases the Pharmacokinetic Exposure and Anticoagulant Effect of Dabigatran in HIV-Negative Healthy Volunteers. Circulation. 2016 Dec 6;134(23):1909-1911.

Hadigan C, Paules CI, Fauci AS. Association Between Human Immunodeficiency Virus Infection and Cardiovascular Diseases: Finding a Solution to Double Jeopardy. JAMA Cardiol. 2017 Feb 1;2(2):123-124.

Thiara DK, Liu CY, Rama F, Mangat S, Purdy JB, Duarte HA, Schmidt N, Hur J, Sibley CT, Bluemke DA, Hadigan C. Abnormal myocardial function is related to myocardial steatosis and diffuse myocardial fibrosis in HIV-Infected adults. J Infect Dis. 2015 Nov 15;212(10):1544-51.

Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with HIV disease. J Clin Endocrinol Metab. 2007 Jul;92(7):2506-12. Epub 2007 Apr 24.

Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Effects of rosiglitazone on metabolic indices and fat in HIV lipodystrophy: A randomized controlled trial. Ann Intern Med, May 2004; 140: 786 – 794

Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA 2000;284(4):472-77.